O	0	10	Randomised
O	11	16	trial
O	16	17	:
O	18	26	survival
O	27	34	benefit
O	35	38	and
O	39	45	safety
O	46	48	of
B-intervention	49	57	adjuvant
I-intervention	58	62	dose
I-intervention	62	63	-
I-intervention	63	68	dense
I-intervention	69	81	chemotherapy
O	82	85	for
O	86	90	node
O	90	91	-
O	91	99	positive
O	100	106	breast
O	107	113	cancer
O	113	114	.

O	115	117	We
O	118	127	evaluated
O	128	131	the
O	132	140	survival
O	141	148	benefit
O	148	149	,
O	150	156	safety
O	156	157	,
O	158	169	feasibility
O	169	170	,
O	171	174	and
O	175	187	tolerability
O	188	190	of
O	191	195	dose
O	195	196	-
O	196	201	dense
O	202	203	(
O	203	205	DD
O	205	206	)
O	207	215	adjuvant
O	216	228	chemotherapy
O	229	233	with
O	234	244	epirubicin
O	245	248	and
O	249	259	paclitaxel
O	260	263	for
B-eligibility	264	269	women
I-eligibility	270	274	with
I-eligibility	275	279	node
I-eligibility	279	280	-
I-eligibility	280	288	positive
I-eligibility	289	296	primary
I-eligibility	297	303	breast
I-eligibility	304	310	cancer
O	310	311	.

O	312	322	Randomised
O	323	331	patients
O	332	333	(
O	333	334	n
O	334	335	=
B-total-participants	335	338	216
O	338	339	)
O	340	348	received
O	349	351	DD
O	352	354	or
B-control	355	367	conventional
I-control	367	368	-
I-control	368	376	schedule
I-control	377	378	(
I-control	378	380	CS
I-control	380	381	)
I-control	382	394	chemotherapy
O	394	395	.

O	396	400	Dose
O	400	401	-
O	401	406	dense
O	407	414	regimen
O	415	423	patients
O	424	425	(
O	425	426	n
O	426	427	=
B-intervention-participants	427	430	108
O	430	431	)
O	432	440	received
O	441	451	epirubicin
O	452	454	90
O	455	457	mg
O	458	459	m
O	459	460	-
O	460	461	2
O	462	466	plus
O	467	477	paclitaxel
O	478	481	175
O	482	484	mg
O	485	486	m
O	486	487	-
O	487	488	2
O	489	491	in
O	492	496	four
O	497	499	14
O	499	500	-
O	500	503	day
O	504	510	cycles
O	510	511	,
O	512	516	then
O	517	533	cyclophosphamide
O	534	537	600
O	538	540	mg
O	541	542	m
O	542	543	-
O	543	544	2
O	544	545	,
O	546	558	methotrexate
O	559	561	40
O	562	564	mg
O	565	566	m
O	566	567	-
O	567	568	2
O	568	569	,
O	570	573	and
O	574	586	fluorouracil
O	587	590	600
O	591	593	mg
O	594	595	m
O	595	596	-
O	596	597	2
O	598	599	(
O	599	602	CMF
O	603	606	600
O	606	607	/
O	607	609	40
O	609	610	/
O	610	613	600
O	613	614	)
O	615	617	in
O	618	623	three
O	624	626	14
O	626	627	-
O	627	630	day
O	631	637	cycles
O	637	638	,
O	639	643	plus
O	644	654	filgrastim
O	655	656	5
O	657	663	microg
O	664	666	kg
O	667	670	day
O	670	671	-
O	671	672	1
O	673	675	as
O	676	682	growth
O	683	690	support
O	691	693	in
O	694	699	every
O	700	705	cycle
O	705	706	.

O	707	719	Conventional
O	719	720	-
O	720	728	schedule
O	729	736	regimen
O	737	745	patients
O	746	747	(
O	747	748	n
O	748	749	=
B-control-participants	749	752	108
O	752	753	)
O	754	762	received
O	763	773	epirubicin
O	774	776	90
O	777	779	mg
O	780	781	m
O	781	782	-
O	782	783	2
O	784	788	plus
O	789	805	cyclophosphamide
O	806	809	600
O	810	812	mg
O	813	814	m
O	814	815	-
O	815	816	2
O	817	819	in
O	820	824	four
O	825	827	21
O	827	828	-
O	828	831	day
O	832	838	cycles
O	838	839	,
O	840	844	then
O	845	848	CMF
O	849	852	600
O	852	853	/
O	853	855	40
O	855	856	/
O	856	859	600
O	860	862	in
O	863	868	three
O	869	871	21
O	871	872	-
O	872	875	day
O	876	882	cycles
O	882	883	,
O	884	888	plus
O	889	899	filgrastim
O	900	902	if
O	903	911	required
O	911	912	.

O	913	918	After
O	919	920	a
O	921	927	median
O	928	934	follow
O	934	935	-
O	935	937	up
O	938	940	of
O	941	943	38
O	943	944	.
O	944	945	4
O	946	952	months
O	952	953	,
O	954	956	71
O	957	965	patients
O	966	967	(
O	967	969	33
O	969	970	%
O	970	971	)
B-outcome	972	980	relapsed
I-outcome	981	983	or
I-outcome	984	988	died
O	988	989	:
O	990	992	DD
O	992	993	,
B-iv-bin-abs	994	996	33
O	997	1005	patients
O	1006	1007	(
B-iv-bin-abs	1007	1009	15
O	1010	1016	deaths
O	1016	1017	)
O	1017	1018	;
O	1019	1021	CS
O	1021	1022	,
B-cv-bin-abs	1023	1025	38
O	1026	1034	patients
O	1035	1036	(
B-cv-bin-abs	1036	1038	22
O	1039	1045	deaths
O	1045	1046	)
O	1046	1047	.

O	1048	1052	Dose
O	1053	1058	dense
O	1059	1065	showed
O	1066	1067	a
O	1068	1073	trend
O	1074	1077	for
O	1078	1086	improved
B-outcome	1087	1094	disease
I-outcome	1094	1095	-
I-outcome	1095	1099	free
I-outcome	1100	1108	survival
I-outcome	1109	1110	(
I-outcome	1110	1113	DFS
I-outcome	1113	1114	)
O	1115	1118	and
B-outcome	1119	1126	overall
I-outcome	1127	1135	survival
I-outcome	1136	1137	(
I-outcome	1137	1139	OS
I-outcome	1139	1140	)
O	1140	1141	.

B-outcome	1142	1146	Four
I-outcome	1146	1147	-
I-outcome	1147	1151	year
I-outcome	1152	1157	rates
I-outcome	1158	1160	of
I-outcome	1161	1164	DFS
O	1165	1168	and
B-outcome	1169	1171	OS
O	1172	1176	were
B-iv-bin-percent	1177	1179	64
O	1180	1183	and
B-cv-bin-percent	1184	1186	85
I-cv-bin-percent	1186	1187	%
O	1188	1191	for
O	1192	1194	DD
O	1194	1195	,
O	1196	1199	and
B-iv-bin-percent	1200	1202	58
O	1203	1206	and
B-cv-bin-percent	1207	1209	75
I-cv-bin-percent	1209	1210	%
O	1211	1214	for
O	1215	1217	CS
O	1217	1218	.

O	1219	1222	All
O	1223	1228	seven
O	1229	1235	cycles
O	1236	1240	were
O	1241	1253	administered
O	1254	1256	to
O	1257	1260	208
O	1261	1269	patients
O	1270	1271	(
O	1271	1273	96
O	1273	1274	%
O	1274	1275	)
O	1275	1276	.

B-outcome	1277	1282	Rates
I-outcome	1283	1285	of
I-outcome	1286	1291	cycle
I-outcome	1292	1297	delay
O	1297	1298	,
B-outcome	1299	1314	discontinuation
O	1314	1315	,
B-outcome	1316	1320	dose
I-outcome	1321	1330	reduction
O	1330	1331	,
O	1332	1335	and
B-outcome	1336	1343	adverse
I-outcome	1344	1350	events
O	1351	1355	were
O	1356	1363	similar
O	1364	1366	in
O	1367	1371	both
O	1372	1378	groups
O	1378	1379	.

O	1380	1384	Dose
O	1384	1385	-
O	1385	1390	dense
O	1391	1401	sequential
O	1402	1414	chemotherapy
O	1415	1419	with
O	1420	1430	epirubicin
O	1430	1431	/
O	1431	1441	paclitaxel
O	1442	1446	then
O	1447	1450	CMF
O	1450	1451	,
O	1452	1461	supported
O	1462	1464	by
O	1465	1475	filgrastim
O	1475	1476	,
O	1477	1479	is
O	1480	1484	safe
O	1485	1488	and
O	1489	1497	improves
O	1498	1506	survival
O	1507	1510	for
O	1511	1519	patients
O	1520	1524	with
O	1525	1529	node
O	1529	1530	-
O	1530	1538	positive
O	1539	1545	breast
O	1546	1552	cancer
O	1552	1553	.
